Nerissa Kreher
CIK 1741850 · View on SEC EDGAR ↗
First SEC filing: Oct. 28, 2021 · Latest: Oct. 28, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 13, 2025 | RZLT | P | 3,076 | $3.25 | $9,997 | 37,576 Direct | +8.92% | Acquired | 48.2% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| July 1, 2026 | XERS | Stock Option (Right to Buy) | Common Stock (37,910) | $8.00 | July 1, 2036 | 37,910 | Acquired |
| Nov. 19, 2025 | RZLT | Director Stock Option (Right to Buy) | Common Shares (12,000) | $10.16 | Nov. 19, 2035 | 12,000 | Acquired |
| June 10, 2025 | RZLT | Director Stock Options (Right to Buy) | Common Shares (5,000) | $4.39 | June 10, 2035 | 5,000 | Acquired |
| Feb. 16, 2025 | RZLT | Director Stock Option (Right to Buy) | Common Shares (15,000) | $4.61 | Feb. 16, 2035 | 15,000 | Acquired |
| Jan. 23, 2024 | RZLT | Director Stock Options (Right to Buy) | Common Shares (30,000) | $1.02 | Jan. 23, 2034 | 30,000 | Acquired |
| July 1, 2022 | TRDA | Stock Option (Right to Buy) | Common stock (31,032) | $12.00 | July 1, 2032 | 31,032 | Acquired |
| March 1, 2022 | TRDA | Stock Option (Right to Buy) | Common stock (62,063) | $11.57 | March 1, 2032 | 62,063 | Acquired |
| Dec. 29, 2021 | TRDA | Stock Option (Right to Buy) | Common Stock (5,200) | $2.10 | Dec. 1, 2030 | 5,200 | Disposed |
| Oct. 28, 2021 | TRDA | Stock Option (Right to Buy) | Common stock (72,012) | $20.00 | Oct. 28, 2031 | 72,012 | Acquired |
| Oct. 8, 2018 | TECX | Stock Option (Right to Buy) | Common Stock (2,942) | $0.91 | June 12, 2027 | 2,942 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Oct. 28, 2021 | TRDA | Stock Option (Right to Buy)→ Common Stock (147,922) | 147,922 | Direct |
| Oct. 28, 2021 | TRDA | Stock Option (Right to Buy)→ Common Stock (63,826) | 63,826 | Direct |
| June 20, 2018 | TECX | Stock Option (Right to Buy)→ Common Stock (85,914) | 85,914 | Direct |
| June 20, 2018 | TECX | Stock Option (Right to Buy)→ Common Stock (27,571) | 27,571 | Direct |
| June 20, 2018 | TECX | Stock Option (Right to Buy)→ Common Stock (59,932) | 59,932 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
TECX
M.D.(10) Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2018 | $366,380 | $109,695 | — | — | — | — | $3,960 | $898,873 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.